|View printer-friendly version|
“Utilizing the CRISPR/Cas9 platform, Charles River clients can work with
a single provider for both the in vivo and in vitro phases
of their research,” said Dr.
Charles River has developed partnerships with three key groups globally
for in vivo model creation services. In
In addition to building a network of partners, Charles River has also prepared a number of academic presentations that showcase their CRISPR/Cas9 expertise, including:
A poster entitled Comparative Analysis of NHEJ and HDR Repair
Pathways for Genomic Editing Using CRISPR/Cas9 Technology in ES Cells
was presented at the CRISPR Genome Editing: From High-throughput
Disease Models Conferencein Copenhagen.
- A second poster, C57BL/6NCrl mouse models generated by CRISPR/Cas9-mediated gene-editing, was presented at the CRISPR Precision Genome Editing Congress Europe 2016.
David Fischer, Executive Director of Biology and DMPK spoke at the World Preclinical Congress Europe meeting. Dr. Fischer’s presentation on Vertical Integration of CRISPR/Cas9 Genome Engineering in Drug Discovery detailed the numerous applications of CRISPR/Cas9 throughout the drug discovery process by exploring examples from Charles River case studies.
Don Liu, Senior Scientist in Charles River’s Genetically Engineered Models and Services group, will speak at CRISPR Summit USA. Dr. Liu’s presentation, Efficient Screening of Mutations Generated by CRISPR/Cas9 Genome Editing, will touch on the limitations of current post-CRISPR screening methods and present a sensitive platform for screening CRISPR-generated mutations for in vitro and in vivo models.
To learn more about Charles River’s strategic CRISPR/Cas9 initiatives, please visit our website.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Charles River Laboratories International, Inc.
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations